科研动态期刊摘要
可调控的膜结合IL-15工程化TIL细胞疗法用于免疫检查点抑制剂耐药的晚期黑色素瘤：1期和1/2期试验的汇总分析
Nature Medicine · 2026-11-04
摘要
《自然·医学》，在线发表：2026年11月03日；doi:10.1038/s41591-026-04743-6 如2026年美国癌症免疫治疗学会年会所报告，在对两项试验进行的非预设汇总分析中，amsokigene autoleucel——一种经工程化改造以消除IL-2需求的自体肿瘤浸润淋巴细胞疗法——成功制备且耐受性良好，并在免疫检查点抑制剂难治性黑色素瘤患者中显示出初步的临床疗效信号。
English
Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials
Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04743-6 As presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting, in a non-prespecified pooled analysis of two trials, amsokigene autoleucel, an autologous tumor-infiltrating lymphocyte therapy engineered to eliminate the need for IL-2, was successfully manufactured and well tolerated and showed a preliminary clinical efficacy signal in patients with immune checkpoint inhibitor-refractory melanoma.